Lung cancer-related fatigue after chemotherapy
Conditions
Interventions
Content Group A (Control Group):Restricted to routine clinical treatment and care after lung cancer chemotherapy.
Group B (Acupuncture Group):Conventional treatment plus acupuncture intervention (selecting acupoints such as Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6), three times a week, each session lasting
Group C (Walking Group):Routine treatment + walking training (conducted under the guidance of a rehabilitation therapist, 5 times per week, 30-40 minutes each session, with intensity adjusted accordin
Group D (Combined Group):Routine treatment + acupuncture intervention + walking training (protocol as in the previous two groups).
Sponsors
Fuyang City Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Confirmed as lung cancer by histopathology or cytology, and currently undergoing or having recently completed a chemotherapy cycle; (2) Aged between 18 and 80 years, with no restriction on gender; (3) Experiencing moderate or higher cancer-related fatigue (total score on the Piper Fatigue Scale =4 points prior to enrollment); (4) Patients with clear consciousness, stable vital signs, and the ability to cooperate with all assessments and interventions; (5) Voluntarily participating in this study and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiovascular diseases, hepatic and renal insufficiency, or other significant organ dysfunction; 2. Patients with severe mental disorders or cognitive dysfunction; 3. Patients with local skin damage or infection, severe acupuncture allergy, or intolerance to acupuncture; 4. Patients with severe bone and joint diseases, motor dysfunction, or other contraindications for walking training; 5. Patients who have recently participated in other similar fatigue intervention studies. 4.3 Dropout and Termination Criteria 1. Occurrence of severe adverse events related to the study intervention; 2. Worsening of the patient's condition requiring a change in the primary anti-tumor treatment plan; 3. Poor compliance (actual number of interventions completed is less than 80% of the total number specified in the protocol).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Piper Fatigue Scale (PFS) Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| SF-36 Health Survey Scoring;Serum inflammatory factors (CRP, IL-6); | — |
Countries
China
Contacts
Public ContactMa Shuming
Fuyang Cancer Hospital
Outcome results
None listed